Today Dimension Therapeutics Inc (DMTX) Stock Rises

September 17, 2017 - By Stephen Andrade

The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) is a huge mover today! The stock increased 3.70% or $0.15 on September 15, reaching $4.2. About 274,207 shares traded. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 83.05% since September 17, 2016 and is downtrending. It has underperformed by 99.75% the S&P500.
The move comes after 6 months positive chart setup for the $105.22M company. It was reported on Sep, 17 by Barchart.com. We have $4.58 PT which if reached, will make NASDAQ:DMTX worth $9.47 million more.

Wall Street await Dimension Therapeutics Inc (NASDAQ:DMTX) to release earnings on November, 9. Analysts forecast earnings per share of $-0.49, up exactly $0.09 or 15.52 % from 2014’s $-0.58 EPS. After posting $-0.49 EPS for the previous quarter, Dimension Therapeutics Inc’s analysts now forecast 0.00 % EPS growth.

Dimension Therapeutics Inc (NASDAQ:DMTX) Ratings Coverage

Among 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Dimension Therapeutics had 9 analyst reports since November 6, 2015 according to SRatingsIntel. Canaccord Genuity initiated the shares of DMTX in report on Monday, November 16 with “Buy” rating. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) earned “Buy” rating by Citigroup on Monday, November 16. The firm has “Buy” rating given on Friday, June 3 by Cantor Fitzgerald. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) earned “Buy” rating by Cantor Fitzgerald on Thursday, February 18. The firm earned “Buy” rating on Monday, November 16 by Goldman Sachs. The firm has “Buy” rating given on Friday, December 4 by Goldman Sachs. Roth Capital initiated the stock with “Buy” rating in Friday, November 6 report.

More important recent Dimension Therapeutics Inc (NASDAQ:DMTX) news were published by: Globenewswire.com which released: “Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase …” on August 31, 2017, also Businesswire.com published article titled: “ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dimension …”, Globenewswire.com published: “Dimension Therapeutics Announces Management Change” on July 24, 2017. More interesting news about Dimension Therapeutics Inc (NASDAQ:DMTX) was released by: Globenewswire.com and their article: “REGENXBIO to Acquire Dimension Therapeutics” with publication date: August 25, 2017.

Dimension Therapeutics, Inc. is a gene therapy company. The company has market cap of $105.22 million. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It currently has negative earnings. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase deficiency, and glycogen storage disease type Ia (GSDIa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.